Shennon Biotechnologies

ShennonBio has developed a proprietary platform that can profile millions of immune cells functionally at the single cell level at unprecedented throughput and accuracy, which resolves a key bottleneck in immunotherapy. We utilize the platform to functionally profile immune cells and their cognate antigens and apply this knowledge to develop more effective therapies against solid tumors and autoimmune diseases. Based in San Francisco next to UCSF Mission Bay, we are funded by DCVC, Foundation Capital and AV8. www.shennonbio.com

Single cell functional profiling,immunotherapy target discovery,ultra high throughput analysis,more effective immunotherapy,and curative treatments for solid tumors

Shennon biotechnologies operates in the Biotechnology research industry.

Shennon biotechnologies's revenue is 11m - 100m

Shennon biotechnologies has 11 - 50 employees.